doi:10.16139/j.1007-9610.2019.05.018

[1] Waks AG, Winer EP.Breast cancer treatment[J]. JAMA,2019,321(3):316.
[2] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials[J]. Lancet,2011,378(9793):771-784.
[3] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials[J]. Lancet,2015,386(10001):1341-1352.
[4] Pan H, Gray R, Braybrooke J, et al.20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med,2017,377(19):1836-1846.
[5] Burstein HJ, Temin S, Anderson H, et al.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update[J]. J Clin Oncol,2014,32(21):2255-2269.
[6] Davies C, Pan H, Godwin J, et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet,2013,381(9869):805-816.
[7] Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[J]. J Clin Oncol,31,2013(suppl;abstr5).
[8] Tormey DC, Gray R, Falkson HC.Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer[J]. J Natl Cancer Inst,1996,88(24):1828-1833.
[9] Stewart HJ, Prescott RJ, Forrest AP.Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years[J]. J Natl Cancer Inst,2001,93(6):456-462.
[10] Fisher B, Dignam J, Bryant J, et al.Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J]. J Natl Cancer Inst,2001,93(9):684-690.
[11] Al-Mubarak M, Tibau A, Templeton AJ, et al.Extended adjuvant tamoxifen for early breast cancer: a meta-analysis[J]. PLoS One,2014,9(2):e88238.
[12] Bartlett J, Sgroi D, Treuner K, et al. Breast Cancer Index predicts benefit of extended endocrine therapy in HR+ breast cancers treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial[J]. Ann Oncol,2019.pii:mdz289.
[13] Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2009,pii: mdz189. doi: 10.1093/annonc/mdz189.
[14] NCCN. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 2.2019) [DB/OL]. [2019-08-02].http://www.nccn.org.
[15] Goss PE, Ingle JN, Martino S, et al.Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17[J]. J Natl Cancer Inst,2005,97(17):1262-1271.
[16] Goss PE, Ingle JN, Pater JL, et al.Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen[J]. J Clin Oncol,2008,26(12):1948-1955.
[17] Mamounas EP, Jeong JH, Wickerham DL, et al.Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial[J]. J Clin Oncol,2008,26(12):1965-1971.
[18] Jakesz R, Greil R, Gnant M, et al.Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a[J]. J Natl Cancer Inst,2007,99(24):1845-1853.
[19] Gray R. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women[EB/OL]. Presented at2018 SABCS, December 4-8, 2018; San Antonio, Abstract GS3-03.[2019-08-02]. https://www.abstracts2view.com/sabcs/view.php?nu=SABCS18L_1589
[20] Sgroi DC, Carney E, Zarrella E, et al.Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker[J]. J Natl Cancer Inst,2013,105(14):1036-1042.
[21] Burstein HJ, Lacchetti C, Anderson H, et al.Adjuvant endocrine therapy for women with hormone receptor-po-sitive breast cancer: ASCO clinical practice guideline focused update[J]. J Clin Oncol,2019,37(5):423-438.
[22] Goss PE, Ingle JN, Pritchard KI, et al.Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med,2016,375(3):209-219.
[23] Mamounas EP, Bandos H, Lembersky BC, et al.Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol,2019,20(1): 88-99
[24] Ohtani S, Iijima K, Higaki K, et al. A prospective randomized multi-center open-label phase Ⅲ trial of exten-ding aromatase-inhibitor adjuvant therapy to 10 years-results from1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)[EB/OL]. Presented at 2018 SABCS, December 4-8, 2018; San Antonio, Abstract GS3-04. [2019-08-02].https://www.abstracts2view.com/sabcs/view.php?nu=SABCS 18L_415
[25] Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine the-rapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05)[J]. J Natl Cancer Inst,2018,110(1).doi: 10.1093/jnci/djx134.
[26] Gnant M, Steger G, Greil R, et al. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial[EB/OL]. Presented at2017 San Antonio Breast Cancer Symposium, December 5-9, 2017; San Antonio, TX. Abstract GS3-01. [2019-08-02].https://www.abstracts2view.com/sabcs17/view.php?nu=SABCS17L_676.
[27] Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial[J]. Lancet Oncol,2017,18(11):1502-1511.
[28] Mastro LD, Mansutti M, Bisagni G, et al. Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase Ⅲ study of Gruppo Italiano Mammella(GIM)[J]. J Clin Oncol,37,2019(suppl;abstr504).
[29] Goldvaser H, Barnes TA, Seruga B, et al.Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis[J]. J Natl Cancer Inst,2018,110(1):31-39.
[30] Dowsett M, Sestak I, Regan MM, et al.Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy: CTS5[J]. J Clin Oncol,2018,36(19):1941-1948.
[31] Richman J, Ring AE, Dowsett M, et al. Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer[J]. J Clin Oncol,37,2019(suppl;abstr514).
[32] Sestak I, Buus R, Cuzick J.Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer a secondary analysis of a rando-mized clinical trial[J]. JAMA Oncol,2018,4(4):545-553.
[33] Zhang Y, Schroeder BE, Jerevall PL, et al.A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes[J]. Clin Cancer Res,2017,23(23):7217-7224.
[34] Curtis C, Shah SP, Chin SF, et al.The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups[J]. Nature,2012,486(7403):346-352.
[35] Rueda OM, Sammut SJ, Seoane JA, et al.Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups[J]. Nature,2019,567(7748):399-404.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 385-386.
[2]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 387-391.
[3]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 392-395.
[4]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 396-402.
[5]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 403-405.
[6]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 406-410.
[7]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 411-415.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 416-420.
[9]	YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei. Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 421-428.
[10]	PAN Ruixin, CHEN Xiaosong, SHEN Kunwei. Study on circulating tumor DNA and circulating tumor cell detecting minimal residual disease in breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 463-467.
[11]	ZHU Siyi, CHEN Xiaosong, SHEN Kunwei. Study on obesity associated with prognosis of early breast cancer and efficacy of adjuvant therapy [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 468-472.
[12]	WANG Jieqiang, MA Dekui. Study on trophoblast cell-surface antigen 2 gene and triple-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 473-477.
[13]	LIU Miao, SHEN Yan, FU Xiaohong, HU Jiaojiao, CHEN Qingqing, YING Tao. A comparative study on breast cancer between smaller and larger diameters using conventional ultrasound and contrast-enhanced ultrasound [J]. Journal of Surgery Concepts & Practice, 2022, 27(3): 229-233.
[14]	CHEN Yuanyuan, YE Xin, TANG Yongzhe, WANG Jie, HE Qi. Prognosis of invasive micropapillary carcinoma versus invasive ductal carcinoma of the breast: a comparative analysis after propensity score matching [J]. Journal of Surgery Concepts & Practice, 2021, 26(04): 353-360.
[15]	CHEN Xiaosong, LI Shuai, WU Jiayi, HUANG Ou, CHAI Weimin, YAO Jiejie, ZHU Ying, XU Chen, CHEN Jiayi, QU Qing, FEI Xiaochun, DING Xiaoyi, LIN Lin, ZHANG Nan, FANG Qiong, HE Jianrong, ZHU Li, LI Yafen, CHEN Weiguo, SHEN Kunwei. Diagnosis, treatment and survival of breast cancer patients in single large hospital: a 10-year analysis [J]. Journal of Surgery Concepts & Practice, 2021, 26(02): 149-158.